<DOC>
	<DOCNO>NCT01430078</DOCNO>
	<brief_summary>The objective study assess bioavailability ASP015K within gastrointestinal tract .</brief_summary>
	<brief_title>A Study Assess Bioavailability ASP015K</brief_title>
	<detailed_description>Each subject participate four separate study period . In period , subject admit clinical unit approximately seven hour day prior give study drug . Subjects remain clinical research unit next 24 hour receive study drug . Subjects return clinical research unit 36 48 hour receive study drug give blood sample . There minimum four day `` washout '' period , study period . Under certain circumstance , subject may ask return clinical research unit additional study period .</detailed_description>
	<criteria>Subject weigh least 45 kg BMI 1832 kg/m2 Subject must demonstrate ability swallow empty size 000 capsule Subject agree sexual abstinence , surgically sterile ( documentation provide healthcare professional ) , use medically acceptable method prevent pregnancy study Subject normal 12lead ECG Subject medically healthy , clinically significant medical history abnormality Subject ever seek advice , refer , General Practitioner ( GP ) counselor abuse misuse alcohol , non medical drug , medicinal drug substance abuse e.g . solvent Subject currently use previous use Class A drug opiates , cocaine , ecstasy , lysergic acid diethylamide ( LSD ) intravenous amphetamine The subject positive drug abuse test result The subject regularly consume alcohol &gt; 21 unit per week The subject current smoker smoke within last 12 month The subject clinically significant abnormal biochemistry , hematology urinalysis The subject history gastrointestinal surgery ( exception appendectomy unless perform within previous 12 month ) The subject history clinically significant cardiovascular , renal , hepatic , respiratory particularly gastrointestinal disease , especially peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn 's Disease Irritable Bowel Syndrome The subject radiation exposure clinical trial exceed 5 mSv last twelve month 10 mSv last five year The subject history adverse reaction allergy study drug excipients The subject suffers hayfever must expect symptom study The subject acute diarrhoea constipation 7 day first study day The subject presence nonremovable metal object metal plate , screw , etc , abdominal region body ( exception sterilisation clip ) The subject positive Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) Human Immunodeficiency virus HIV result The subject treatment prescription drug complementary alternative medicine within 14 day prior study drug administration , counter medication within 7 day prior study drug administration The subject has/had symptomatic , viral , bacterial , fungal infection within 1 week prior clinic check The subject vaccinate within last 90 day The subject participate clinical research study involve investigational drug dosage form within previous 90 day The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 90 day donate plasma within 7 day prior clinic admission The subject past history tuberculosis absence evidence successful TB immunization assess clinical examination Bacille CalmetteGu√©rin ( BCG ) scar The subject past history recurrent herpes simplex varicella zoster infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Pharmacokinetics ASP015K</keyword>
</DOC>